2020
Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors
Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clinical Cancer Research 2020, 26: 6550-6558. PMID: 32998964, PMCID: PMC7744329, DOI: 10.1158/1078-0432.ccr-20-2682.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinCancer SurvivorsCisplatinEtoposideFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGenome-Wide Association StudyHumansIfosfamideMaleMiddle AgedNeoplasmsNeurotoxicity SyndromesPolymorphism, Single NucleotidePrognosisRisk FactorsSurvival RateVinblastineConceptsCumulative cisplatin doseCisplatin doseSevere neurotoxicityCancer survivorsRisk factorsAdult-onset cancer survivorsLifestyle/behavioral factorsCisplatin-induced neurotoxicityDizziness/vertigoNeuro-otological symptomsPeripheral sensory neuropathyPoor overall healthPeripheral motor neuropathyImportant risk factorTesticular cancer survivorsQuality of lifeSerum platinum levelsDose adjustmentMotor neuropathyRaynaud's phenomenonSensory neuropathyNeurotoxicity riskPsychotropic medicationsClinical examinationMedical history
2019
Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.
Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB, _ _. Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2019, 17: 459-468. PMID: 31085753, PMCID: PMC6712564, DOI: 10.6004/jnccn.2018.7109.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCancer SurvivorsGenetic VariationHumansHypogonadismMaleMiddle AgedNeoplasm StagingOdds RatioPatient Outcome AssessmentPatient Reported Outcome MeasuresRisk FactorsTesticular NeoplasmsYoung AdultConceptsTesticular cancer survivorsPlatinum-based chemotherapyRisk factorsErectile dysfunctionCancer survivorsFirst-line platinum-based chemotherapyHealth outcomesMultivariable binary logistic regression analysisCisplatin-based chemotherapy regimenCardiovascular disease risk factorsVigorous-intensity physical activityPrevalence of hypogonadismTestosterone replacement therapyDisease risk factorsSerum testosterone levelsBody mass indexBinary logistic regression analysisYounger median ageAdverse health outcomesLogistic regression analysisYears of ageAnxiety/depressionGenetic risk factorsChemotherapy regimenSymptomatic patients